Viatris (VTRS) Receivables - Net (2019 - 2026)
Viatris (VTRS) posted Receivables - Net of $3.1 billion for Q2 2026, up 1.62% on a QoQ basis from $3.1 billion in Q1 2026, and down 4.05% year-over-year from $3.3 billion in Q2 2025.
Analysis
Viatris (VTRS) Receivables - Net (2019 - 2026) Analysis & Trends
Viatris has reported Receivables - Net for 8 years, with the latest figure at $3.1 billion in Q2 2026.
- On a quarterly basis, Receivables - Net fell 4.05% year-over-year to $3.1 billion in Q2 2026; TTM through Jun 2026 was $3.1 billion, a 4.05% decrease from a year earlier, with the FY2025 full-year figure at $3.0 billion, down 5.9% from the prior year.
- Receivables - Net was $3.1 billion for Q2 2026 at Viatris, up from $3.1 billion in the prior quarter.
- The five-year high for Receivables - Net was $4.1 billion in Q1 2022, with the low at $3.0 billion in Q4 2025.
- Average Receivables - Net over 5 years is $3.5 billion, with a median of $3.5 billion recorded in 2023.
- The sharpest annual moves came in 2022 and 2023: Receivables - Net declined 23.28% in 2022, then increased 12.14% in 2023.
- Over 5 years, Receivables - Net stood at $3.8 billion in 2022, then fell by 2.99% to $3.7 billion in 2023, then slipped by 12.95% to $3.2 billion in 2024, then fell by 5.9% to $3.0 billion in 2025, then advanced by 3.13% to $3.1 billion in 2026.
- The last three Receivables - Net figures came in at $3.1 billion (Q2 2026), $3.1 billion (Q1 2026), and $3.0 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.53 Bn | 38.88 Bn | 2.15 Bn |
| 2 | Viatris | 19.14 Bn | 18.25 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.33 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 400.20 Mn | 358.95 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 178.79 Mn | 178.79 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.13 Bn |
| Mar 31, 2026 | 3.08 Bn |
| Dec 31, 2025 | 3.03 Bn |
| Sep 30, 2025 | 3.37 Bn |
| Jun 30, 2025 | 3.26 Bn |
| Mar 31, 2025 | 3.13 Bn |
| Dec 31, 2024 | 3.22 Bn |
| Sep 30, 2024 | 3.72 Bn |
| Jun 30, 2024 | 3.57 Bn |
| Mar 31, 2024 | 3.63 Bn |
| Dec 31, 2023 | 3.70 Bn |
| Sep 30, 2023 | 3.74 Bn |
| Jun 30, 2023 | 3.61 Bn |
| Mar 31, 2023 | 3.50 Bn |
| Dec 31, 2022 | 3.81 Bn |
| Sep 30, 2022 | 3.33 Bn |
| Jun 30, 2022 | 3.74 Bn |
| Mar 31, 2022 | 4.09 Bn |
| Dec 31, 2021 | 4.27 Bn |
| Sep 30, 2021 | 4.35 Bn |